Ambalal Sarabhai Enterprises Ltd

₹ 34.0 -1.13%

10 Jun 10:33 a.m.

About

Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics^[1]

Key Points

Business Overview:^[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad

Website BSE NSE

Market Cap ₹ 263 Cr.
Current Price ₹ 34.0
High / Low ₹ 38.8 / 23.1
Stock P/E 24.0
Book Value ₹ 7.76
Dividend Yield 0.00 %
ROCE 16.4 %
ROE 20.4 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has delivered good profit growth of 43.9% CAGR over last 5 years

Cons

Stock is trading at 4.39 times its book value
Promoter holding is low: 31.4%
Tax rate seems low
Company has a low return on equity of 12.1% over last 3 years.
Earnings include an other income of Rs.15.6 Cr.
Working capital days have increased from 267 days to 1,379 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	0.37	1.70	0.80	0.33	0.99	1.14	0.00	1.17	1.73	1.64	0.79	0.00	1.52
	1.66	4.84	2.13	1.96	1.64	2.41	1.80	3.74	3.43	2.83	2.43	0.94	2.88
Operating Profit	-1.29	-3.14	-1.33	-1.63	-0.65	-1.27	-1.80	-2.57	-1.70	-1.19	-1.64	-0.94	-1.36
OPM %	-348.65%	-184.71%	-166.25%	-493.94%	-65.66%	-111.40%		-219.66%	-98.27%	-72.56%	-207.59%		-89.47%
	2.60	1.18	1.96	1.33	3.41	1.88	6.37	10.81	-3.21	8.17	1.36	2.89	3.16
Interest	0.05	0.03	0.04	0.06	0.07	0.09	0.09	0.10	0.05	0.07	0.08	0.09	0.17
Depreciation	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.02
Profit before tax	1.23	-2.02	0.56	-0.39	2.66	0.49	4.45	8.12	-4.98	6.89	-0.38	1.84	1.61
Tax %	8.94%	0.00%	0.00%	69.23%	-76.32%	6.12%	3.15%	-3.82%	-0.40%	0.00%	0.00%	-0.54%	-64.60%
	1.12	-2.02	0.56	-0.65	4.70	0.46	4.31	8.43	-4.96	6.88	-0.38	1.84	2.65
EPS in Rs	0.15	-0.26	0.07	-0.08	0.61	0.06	0.56	1.10	-0.65	0.90	-0.05	0.24	0.35
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	15	7	2	1	0	0	0	0	4	4	4	4
	27	29	14	22	9	8	12	6	9	9	11	9
Operating Profit	-12	-22	-13	-21	-9	-8	-12	-6	-5	-5	-7	-5
OPM %	-79%	-310%	-858%	-2,265%				-4,292%	-139%	-126%	-181%	-130%
	14	96	-1	24	6	25	3	9	10	8	16	16
Interest	8	2	3	1	1	0	1	0	0	2	0	0
Depreciation	3	15	2	0	0	0	0	0	0	0	0	0
Profit before tax	-9	58	-19	2	-3	16	-9	3	4	1	8	10
Tax %	0%	21%	10%	166%	13%	2%	-1%	14%	5%	-217%	-2%	-10%
	-9	46	-21	-1	-4	16	-9	3	4	3	8	11
EPS in Rs	-1.19	5.96	-2.68	-0.19	-0.51	2.03	-1.23	0.39	0.54	0.34	1.08	1.43
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-6%
5 Years:	%
3 Years:	2%
TTM:	-2%

Compounded Profit Growth
10 Years:	9%
5 Years:	44%
3 Years:	32%
TTM:	264%

Stock Price CAGR
10 Years:	17%
5 Years:	-5%
3 Years:	14%
1 Year:	-8%

Return on Equity
10 Years:	2%
5 Years:	12%
3 Years:	12%
Last Year:	20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	77	77	77	77	77	77	77	77	77	77	77	77
Reserves	-73	-28	-46	-48	-52	-36	-46	-43	-39	-36	-28	-17
	30	30	22	11	11	11	11	10	11	10	8	11
	103	65	64	91	103	73	58	40	30	31	27	15
Total Liabilities	136	144	116	131	139	125	100	83	80	81	83	86
	43	21	16	15	15	14	14	13	13	13	12	12
CWIP	0	0	0	0	0	0	0	0	0	0	0	0
Investments	56	83	76	56	56	56	27	26	26	25	25	25
	37	40	24	60	68	54	60	44	41	43	45	48
Total Assets	136	144	116	131	139	125	100	83	80	81	83	86

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-12	-69	-4	-13	-3	-5	-10	-8	2	-4	-4	-0
	13	75	9	26	2	5	16	21	1	3	6	-3
	-1	-3	-8	-12	-0	-0	-0	-16	-4	0	-2	3
Net Cash Flow	-0	3	-3	1	-1	-0	5	-3	-2	-0	-0	0
Free Cash Flow	-0	31	-3	2	-3	-4	1	11	2	-4	1	-0
CFO/OP	71%	304%	27%	-24%	-11%	51%	85%	128%	-45%	65%	47%	5%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	37	2	0	0				421	30	37	37	39
Inventory Days	76	23	48	57				0	2	0	0	7
Days Payable	321	729	3,974	13,253					1,612			712
Cash Conversion Cycle	-207	-705	-3,927	-13,197				421	-1,580	37	37	-667
Working Capital Days	-2,355	-3,036	-16,106	-23,785				-30,660	-1,038	-687	109	1,379
ROCE %	-34%	-60%	-13%	-22%	-7%	37%	-4%	10%	11%	6%	6%	16%

Insights

In beta

Mar 2014

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Domestic Revenue (Geographical Segment)
₹ Lakhs

x,xxx.xx	x,xxx.xx	xx,xxx.xx	xx,xxx.xx	x,xxx.xx	xx,xxx.xx	x,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx	xx,xxx.xx
x,xxx.xx	x,xxx.xx	xx,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx
					x	x	xx		xx		xx
				xx					xxx	xxx	xxx
		xxx	xx

Please log in to see hidden values.

Export Revenue (Geographical Segment)
₹ Lakhs

IVD Approved Molecular Tests (CoSara Diagnostics)
Number

Number of Internationally Registered Products (Asence Group)
Number

Number of New Product Registrations (Global)
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

3 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	30.78%	30.78%	30.78%	30.78%	30.78%	31.35%	31.35%	31.35%	31.35%	31.35%	31.36%	31.36%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.38%	0.38%	0.34%	0.34%	0.00%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.10%	0.00%	0.00%	0.00%	0.00%
	69.22%	69.23%	69.21%	69.23%	69.22%	68.65%	68.54%	68.18%	68.26%	68.32%	68.29%	68.64%
No. of Shareholders	1,77,743	1,75,222	1,71,944	1,70,079	1,69,228	1,72,338	1,71,221	1,70,912	1,69,630	1,70,015	1,68,396	1,67,599

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	30.75%	30.75%	30.76%	30.76%	30.76%	30.76%	30.77%	30.78%	31.35%	31.36%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.38%	0.00%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%	0.00%	0.10%	0.00%
	69.25%	69.25%	69.24%	69.24%	69.24%	69.24%	69.22%	69.23%	68.18%	68.64%
No. of Shareholders	1,66,010	1,64,094	1,61,546	1,60,045	1,64,156	1,81,213	1,78,274	1,70,079	1,70,912	1,67,599

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports